title: Prophylactic effects of quercetin and hyperoside in a calcium oxalate stone forming rat model.
abstract: Quercetin and hyperoside (QH) are the two main constituents of the total flavone glycosides of Flos Abelmoschus manihot, which has been prescribed for treating chronic kidney disease for decades. This study aimed to investigate the effect of QH on calcium oxalate (CaOx) formation in ethylene glycol (EG)-fed rats. Rats were divided into three groups: an untreated stone-forming group, a QH-treated stone-forming group (20 mg/kg/day) and a potassium citrate-treated stone-forming group (potassium citrate was a worldwide-recognized calculi-prophylactic medicine). Ethylene glycol (0.5 %) was administered to the rats during the last week, and vitamin D3 was force-fed to induce hyperoxaluria and kidney calcium oxalate crystal deposition. 24 h urine samples were collected before and after inducing crystal deposits. Rats were killed and both kidneys were harvested after 3 weeks. Bisected kidneys were examined under a polarized light microscope for semi-quantification of the crystal-formation. The renal tissue superoxide dismutase and catalase levels were measured by Western blot. QH and potassium citrate have the ability to alkalinize urine. The number of crystal deposits decreased significantly in the QH-treated stone-forming group as compared to the other groups. Superoxide dismutase and catalase levels also increased significantly in the QH-treated stone-forming group, as compared with the untreated stone-forming group. QH administration has an inhibitory effect on the deposition of CaOx crystal in EG-fed rats and may be effective for preventing stone-forming disease.
authors.affiliation: Department of Urological Surgery, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China, olegoalegend@gmail.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.forename: Yun-fei
authors.initials: YF
authors.lastname: Xu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Feng
authors.forename: Bo
authors.initials: B
authors.lastname: Peng
authors.forename: Jian-ping
authors.initials: JP
authors.lastname: Che
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.forename: Jun-hua
authors.initials: JH
authors.lastname: Zheng
mesh_terms: D000818:Animals; D002129:Calcium Oxalate / Q000378:metabolism*; D002374:Catalase / Q000378:metabolism; D004195:Disease Models, Animal; D019855:Ethylene Glycol / Q000009:adverse effects; D007668:Kidney / Q000378:metabolism; D007669:Kidney Calculi / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control*; D011794:Quercetin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D002129:Calcium Oxalate; C021304:hyperoside; D011794:Quercetin; D002374:Catalase; D013482:Superoxide Dismutase; D019855:Ethylene Glycol
references.citation: Exp Ther Med. 2014 Sep;8(3):727-730
references.pmid: 25120589
references.citation: BJU Int. 2000 Apr;85(6):621-5
references.pmid: 10759652
references.citation: Pharmacognosy Res. 2014 Jan;6(1):36-41
references.pmid: 24497740
references.citation: PLoS One. 2013 May 22;8(5):e63784
references.pmid: 23717483
references.citation: Arch Ital Urol Androl. 2011 Mar;83(1):1-5
references.pmid: 21585160
references.citation: Int Braz J Urol. 2009 Jul-Aug;35(4):396-405
references.pmid: 19719854
references.citation: Pharm Biol. 2011 Dec;49(12):1224-33
references.pmid: 21846174
references.citation: Southeast Asian J Trop Med Public Health. 2001 Sep;32(3):654-60
references.pmid: 11944733
references.citation: Urolithiasis. 2013 Aug;41(4):279-94
references.pmid: 23754513
references.citation: Ann Intern Med. 2013 Apr 2;158(7):535-43
references.pmid: 23546565
references.citation: Oncol Rep. 2014 Jan;31(1):117-24
references.pmid: 24173369
references.citation: BJU Int. 2002 Jun;89(9):829-34
references.pmid: 12010223
references.citation: J Ethnopharmacol. 2010 May 4;129(1):38-45
references.pmid: 20138208
references.citation: Int J Nanomedicine. 2013;8:909-18
references.pmid: 23467267
references.citation: J Oleo Sci. 2013;62(11):961-71
references.pmid: 24200945
references.citation: Clin J Am Soc Nephrol. 2009 Mar;4(3):680-4
references.pmid: 19261817
references.citation: Urology. 2013 Jul;82(1):33-7
references.pmid: 23602798
references.citation: J Agric Food Chem. 2013 Jul 31;61(30):7258-67
references.pmid: 23876017
references.citation: Urol Res. 2010 Apr;38(2):89-96
references.pmid: 20221591
references.citation: Int J Med Sci. 2014 Jan 28;11(3):282-90
references.pmid: 24516353
references.citation: J Urol. 2008 Apr;179(4):1620-6
references.pmid: 18295251
references.citation: Adv Pharm Bull. 2013;3(1):217-25
references.pmid: 24312839
references.citation: Urolithiasis. 2013 Feb;41(1):91-3
references.pmid: 23532431
references.citation: Urology. 2013 Aug;82(2):489.e1-7
references.pmid: 23796398
references.citation: Kidney Int. 2011 Mar;79(5):538-45
references.pmid: 21085110
references.citation: BMC Complement Altern Med. 2013 Sep 17;13:228
references.pmid: 24044655
references.citation: Urol Res. 2009 Feb;37(1):1-6
references.pmid: 19005647
references.citation: J Med Food. 2012 May;15(5):461-8
references.pmid: 22439874